Multiple System Atrophy and Progressive Supranuclear Palsy: Diminished Striatal D2 Dopamine Receptor Activity Demonstrated by 123I-IBZM Single Photon Emission Computed Tomography

Archives of Neurology

Volumn 50, Issue 5, 1993, Pages 513-516

  Van Royen, Eric ^a   Verhoeff, Nicolaas F L G ^a   Speelman, Johannes D ^b   Wolters, Erik Ch ^c   Kuiper, Michael A ^c   Janssen, Anthonius G M ^d  

^a Departments of Nuclear Medicine   (United States)

^b Neurology ^*  (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 6 METHOXY N [(1 ETHYL 2 PYRROLIDINYL)METHYL) BENZAMIDE; BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; IODINE 123; IODINE 125; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; HUMAN; OCCIPITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR AFFINITY; RECEPTOR DENSITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; BENZAMIDES; CENTRAL NERVOUS SYSTEM; HUMAN; MIDDLE AGE; PARKINSON DISEASE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SUPPORT, NON-U.S. GOV'T; SUPRANUCLEAR PALSY, PROGRESSIVE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0027258719     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1993.00540050063017     Document Type: Article

References (17)

1. Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry. 1989;special suppl:78-89.
2. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333-350.
3. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-DOPA uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547-555.
4. Bokobza B, Ruberg M, Scatton B, et al. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol. 1984;99:167-175.
5. Baron JC, Maziere B, Loc'h C, et al. Loss of striatal (76Br)-bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab. 1986;6:131-136.
6. Kung HF, Pan S, Kung MP, et al. In vitro and in vivo evaluation of (123I)-IBZM, a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med. 1989;30:88-92.
7. Costa DC, Verhoeff NPLG, Cullum ID, et al. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans. Eur J Nucl Med. 1990;16:813-816.
8. Verhoeff NPLG, Bobeldijk, Feenstra MGP, et al. In vitro and in vivo D2dopamine receptor binding with (123I)-IBZM in rat and human brain. Nucl Med Biol. 1991;18:837-846.
9. Bobeldijk M, Verhoeff NPLG, Vekemans JAJM, et al. A simple and high-yield synthesis of (S)-BZM, (R)-BZM and (S)-IBZM for the preparation of (S)-123I-IBZM. J Label Comp Radiopharm. 1990;28:1247-1256.
10. Schaltenbrand G, Wahren W. Atlas for Stereotaxy of the Human Brain. 2nd ed. Stuttgart, Germany: George Thieme Publisher; 1977.
11. Matsui T, Hirano A. An Atlas of the Human Brain for Computerised Tomography. Stuttgart, Germany: Gustav Fischer Verlag; 1978.
12. Lidow MS, Goldman-Rakic PS, Rakic P, Innis RB. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with (3H) raclopride. Proc Natl Acad Sci U S A. 1989;86:6412-6416.
13. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
14. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. 1991;11:220-228.
15. Schwartz J, Tatsch K, Arnold G, et al. 123I-iodobenzamide SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology. 1992;42:556-561.
16. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990;336:32-34.
17. Pastakia B, Polinsky R, Di Chiro G, et al. Multiple system atrophy (Shy-Dräger syndrome): MR imaging. Radiology. 1986;159:499-502.